Compare · AXSM vs CAPR
AXSM vs CAPR
Side-by-side comparison of Axsome Therapeutics Inc. (AXSM) and Capricor Therapeutics Inc. (CAPR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXSM and CAPR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AXSM is the larger of the two at $11.84B, about 10.5x CAPR ($1.13B).
- Over the past year, AXSM is up 106.0% and CAPR is up 182.0% - CAPR leads by 76.0 points.
- Both names hit the wire about 7 times in the past 4 weeks.
- AXSM has more recent analyst coverage (25 ratings vs 9 for CAPR).
- Company
- Axsome Therapeutics Inc.
- Capricor Therapeutics Inc.
- Price
- $229.98-2.90%
- $19.43+1.57%
- Market cap
- $11.84B
- $1.13B
- 1M return
- -8.72%
- -25.38%
- 1Y return
- +106.00%
- +182.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 7
- 7
- Recent ratings
- 25
- 9
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Capricor Therapeutics Inc.
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.
Latest AXSM
- Axsome Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
- Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
- Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
- Chief Executive Officer Tabuteau Herriot exercised 49,666 shares at a strike of $4.95 and sold $11,932,256 worth of shares (49,666 units at $240.25) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Axsome Therapeutics Inc.
- Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
- Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
- Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
- Director Jeffs Roger sold $141,656 worth of shares (572 units at $247.65) as part of a pre-agreed trading plan, decreasing direct ownership by 0.97% to 58,367 units (SEC Form 4)
Latest CAPR
- Capricor Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- CHIEF FINANCIAL OFFICER Bergmann Anthony exercised 24,100 shares at a strike of $3.18 and sold $732,158 worth of shares (24,100 units at $30.38) as part of a pre-agreed trading plan (SEC Form 4)
- EVP, GENERAL COUNSEL Krasney Karen exercised 24,100 shares at a strike of $3.18 and sold $732,158 worth of shares (24,100 units at $30.38) as part of a pre-agreed trading plan (SEC Form 4)
- Capricor Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
- CHIEF FINANCIAL OFFICER Bergmann Anthony exercised 900 shares at a strike of $3.18 and sold $27,000 worth of shares (900 units at $30.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP, GENERAL COUNSEL Krasney Karen exercised 900 shares at a strike of $3.18 and sold $27,000 worth of shares (900 units at $30.00) as part of a pre-agreed trading plan (SEC Form 4)
- Capricor Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Capricor Therapeutics to Present at Upcoming Investor Conferences
- SEC Form 4 filed by CHIEF COMMERCIAL OFFICER Maurer Michael T